As soon as I entered complete remission for multiple myeloma, I felt a glimmer of hope. The word "remission" carries a sense of hope and relief, like the first ray of sunshine breaking through the ...

"Therapeutic innovations like elranatamab achieve a lasting response in 61% of patients with multiple myeloma and complete remission in 30%," said Dr María Victoria Mateos, a consultant physician in ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell ...

Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years. For nearly 30 years, Dr. Jim Omel has had a front row seat to the ...

CHICAGO — The anticipated release of 5-year overall survival (OS) data from the CARTITUDE-1 trial showed that the use of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed or refractory ...

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease from universally fatal to curable for a substantial proportion of patients.

Multiple myeloma is a rare type of blood cancer that starts in your plasma cells. Your plasma cells are a type of white blood cell inside your bone marrow, the soft inner part of your bones. If you ...

At age 89, Cal Crow plays water volleyball three days a week, then chases that with a 1,000-foot swim; on his off days, he logs at least a mile around his neighborhood — and that’s with a cancer ...

In this study, researchers aimed to determine whether patients with standard-risk relapsed/refractory multiple myeloma had improved survival with earlier-line cilta-cel therapy.